Cancer Family
Pancreaticobiliary Neoplasm
CI-CAN-00000309Explore in graph →
Non-malignant1,204 active trials11 approved drugs92 evidence items
- NCIt
- C223357
Loading cancer entity…
Cancer Family
CI-CAN-00000309Explore in graph →
Clinical trials
5,004 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05055323 | A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer | active not recruiting | Phase 1 | 20 | Thomas Jefferson UniversityOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03704662 | Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma | active not recruiting | N/A | 102 | Medical College of WisconsinOTHER | 1 | Jul 20, 2026 |
| clinicaltrials |
| NCT06607185 | A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | active not recruiting | Phase 1 | 750 | Eli Lilly and CompanyINDUSTRY | 8 | Jul 20, 2026 | clinicaltrials |
| NCT03856658 | Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases | active not recruiting | Phase 2 | 14 | Corewell Health WestOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03716531 | Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients With Pancreatic Cancer With Vascular Involvement(PACER) | active not recruiting | N/A | 199 | Massachusetts General HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03816163 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | active not recruiting | Phase 2 | 393 | Astellas Pharma Global Development, Inc.INDUSTRY | 13 | Jul 14, 2026 | clinicaltrials |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | active not recruiting | Phase 1 | 13 | University of PennsylvaniaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT05277766 | Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer(PIPAC-NAL-IRI) | active not recruiting | Phase 1 | 45 | University Hospital, GhentOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04233866 | Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread | active not recruiting | Phase 2 | 176 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05355298 | ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer | active not recruiting | Phase 1 / Phase 2 | 62 | Amplia Therapeutics LimitedINDUSTRY | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05411094 | Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 2 | Jul 10, 2026 | clinicaltrials |
| NCT05726864 | A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors(AMPLIFY-7P) | active not recruiting | Phase 1 / Phase 2 | 158 | Elicio TherapeuticsINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05632328 | AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC | active not recruiting | Phase 2 | 24 | Bruno BockornyOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06147037 | A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | active not recruiting | Phase 1 | 13 | AstraZenecaINDUSTRY | 2 | Jul 7, 2026 | clinicaltrials |
| NCT04477343 | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | active not recruiting | Phase 1 | 20 | University of RochesterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05948475 | Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma(FIRST-308) | active not recruiting | Phase 3 | 200 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 13 | Jul 6, 2026 | clinicaltrials |
| NCT04427761 | A Study of the Life Changes Experienced by Patients With Pancreatic Cancer | active not recruiting | — | 55 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05724563 | Domvanalimab and Zimberelimab in Advanced Liver Cancers | active not recruiting | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT06001268 | Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)(STRONG-PCS) | active not recruiting | N/A | 80 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04098081 | 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma | active not recruiting | Phase 2 | 15 | University of Maryland, BaltimoreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07658586 | AI Multimodal Model for Liver Cancer Diagnosis and Prognosis(AIM-LCAP) | active not recruiting | — | 600 | Guangxi Medical UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06015724 | Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer(DARANIVOVAX) | active not recruiting | Phase 2 | 19 | Georgetown UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03851133 | Florida Pancreas Collaborative Next Generation Biobank | active not recruiting | — | 500 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07122466 | Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy | active not recruiting | — | 24 | Northwell HealthOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07457541 | Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI | active not recruiting | Phase 1 | 15 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05497778 | A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. | active not recruiting | Phase 1 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03872947 | A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 138 | Toray Industries, IncINDUSTRY | 2 | Jun 23, 2026 | clinicaltrials |
| NCT03991832 | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors(SOLID) | active not recruiting | Phase 2 | 58 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06783140 | Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer(PLATINUM-CAN) | active not recruiting | Phase 2 / Phase 3 | 10 | University Health Network, TorontoOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT02151084 | A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer | active not recruiting | Phase 2 | 57 | University Health Network, TorontoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05143970 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors(CHANCES) | active not recruiting | Phase 1 | 27 | Institut Paoli-CalmettesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06381154 | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer | active not recruiting | Phase 2 | 24 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05038254 | Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events | active not recruiting | N/A | 750 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07646717 | Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma(LPHAIC for ICC) | active not recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT03104439 | Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | active not recruiting | Phase 2 | 84 | Massachusetts General HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04560712 | Acupuncture for the Management of Postoperative Pain in Patients With Pancreatic or Colorectal Cancer Undergoing Surgery | active not recruiting | N/A | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05827055 | Proglumide and Chemotherapy for Metastatic Pancreatic Cancer(ProGem) | active not recruiting | Phase 2 | 30 | Georgetown UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06643715 | Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro" | active not recruiting | N/A | 100,000 | Zhejiang UniversityOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT04753879 | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | active not recruiting | Phase 2 | 38 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07076121 | A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | active not recruiting | Phase 2 / Phase 3 | 470 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 3, 2026 | clinicaltrials |
| NCT02379377 | 18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant | active not recruiting | Phase 1 | 110 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)(RASolute 302) | active not recruiting | Phase 3 | 500 | Revolution Medicines, Inc.INDUSTRY | 7 | Jun 2, 2026 | clinicaltrials |
| NCT02451982 | Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas | active not recruiting | Phase 2 | 76 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03257761 | Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer | active not recruiting | Phase 1 | 55 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03801083 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers | active not recruiting | Phase 2 | 4 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | active not recruiting | Phase 2 | 20 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06360354 | A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)(MTAPESTRY 103) | active not recruiting | Phase 1 | 120 | AmgenINDUSTRY | 16 | Jun 1, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 21, 2026source: clinicaltrials